Affinage

UBAC1

Ubiquitin-associated domain-containing protein 1 · UniProt Q9BSL1

Length
405 aa
Mass
45.3 kDa
Annotated
2026-06-10
100 papers in source corpus 2 papers cited in narrative 7 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 4/4 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

UBAC1 (KPC2) is a multidomain adaptor subunit of the KPC ubiquitin ligase complex that couples polyubiquitylated substrates to E3-mediated degradation during cell cycle control (PMID:16227581). It binds the catalytic subunit KPC1 through its UBL domain and engages the 26S proteasome through its UBL and N-terminal UBA domains, while its UBA domains capture polyubiquitylated cargo (PMID:16227581); the KPC1 interaction stabilizes KPC1 in a manner requiring the UBAC1 STI1 domain (PMID:16227581). Functionally, UBAC1 drives degradation of the CDK inhibitor p27 at G1: its STI1 domain is required for efficient p27 polyubiquitylation in vitro, and its N-terminal UBA domain is essential for p27 degradation in cells (PMID:16227581). Beyond cell-cycle control, UBAC1 is recruited to the C-terminal cytoplasmic region of CD95 (Fas) independently of CD95L, where it acts as an adaptor to bring together KPC1 and RelA, promoting partial proteolysis of p105 (NF-κB1) into p50 and formation of inhibitory p50 homodimers that repress NF-κB transcription (PMID:34917906); loss of CD95 releases UBAC1, limiting p50/p50 formation and de-repressing NF-κB-driven cytokine production in triple-negative breast cancer cells (PMID:34917906).

Mechanistic history

Synthesis pass · year-by-year structured walk · 6 steps
  1. 2005 High

    Established UBAC1 as the substrate- and proteasome-bridging subunit of the KPC ligase by defining which domains contact KPC1, the proteasome, and ubiquitin chains.

    Evidence Co-immunoprecipitation, domain-deletion mutants, and in vitro polyubiquitylation in cells

    PMID:16227581

    Open questions at the time
    • No structural model of the UBL/UBA-domain interactions
    • Affinity and chain-linkage selectivity of the UBA domains not quantified
  2. 2005 Medium

    Showed that UBAC1 binding does not merely scaffold but stabilizes the catalytic partner KPC1, identifying the STI1 domain as the determinant of this stabilization.

    Evidence STI1-deletion mutants with KPC1 protein-stability readout on co-expression

    PMID:16227581

    Open questions at the time
    • Mechanism by which STI1 stabilizes KPC1 unresolved
    • Single publication, no orthogonal stability assay reported
  3. 2005 High

    Mapped the domain requirements for catalytic output versus cargo handling, distinguishing the STI1 domain (required for p27 polyubiquitylation) from individual UBA domains (dispensable in vitro).

    Evidence In vitro reconstituted ubiquitylation with domain-deletion mutants

    PMID:16227581

    Open questions at the time
    • Why STI1 is needed for polyubiquitylation mechanistically unclear
    • In vitro requirements not fully matched to cellular requirements
  4. 2005 High

    Connected UBAC1 to a defined physiological output by demonstrating its requirement for G1 p27 degradation and pinpointing the N-terminal UBA domain as essential in cells.

    Evidence RNAi knockdown with domain-mutant rescue and cell-cycle analysis

    PMID:16227581

    Open questions at the time
    • Other physiological substrates beyond p27 not identified
    • Discrepancy between cellular UBA requirement and in vitro dispensability unexplained
  5. 2021 Medium

    Extended UBAC1 function beyond the cell cycle by identifying it as a CD95 interactor that acts as an adaptor coupling KPC1 and RelA to control NF-κB signaling.

    Evidence Unbiased proteomics, reciprocal Co-IP with deletion constructs, and NF-κB reporter/p105-p50 immunoblot

    PMID:34917906

    Open questions at the time
    • Direct UBAC1-CD95 binding interface not structurally defined
    • Whether p105-to-p50 processing uses the same KPC catalytic mechanism as p27 unknown
    • Single lab
  6. 2021 Medium

    Demonstrated the biological consequence of UBAC1 sequestration by showing CD95 loss releases UBAC1, reduces inhibitory p50 homodimers, and activates pro-inflammatory NF-κB output in TNBC.

    Evidence CD95 knockdown/knockout in TNBC cells with NF-κB activity and cytokine ELISA

    PMID:34917906

    Open questions at the time
    • In vivo relevance to tumor behavior not established
    • Quantitative link between UBAC1 availability and p50 dimer abundance not measured

Open questions

Synthesis pass · forward-looking unresolved questions
  • The full substrate repertoire of the UBAC1-KPC complex and the structural basis for how a single adaptor switches between cell-cycle (p27) and NF-κB (p105) regulatory programs remain unresolved.
  • No structural model of UBAC1 in either complex
  • Regulation of UBAC1 partitioning between KPC and CD95 contexts unknown
  • Substrates beyond p27 and p105 uncharacterized in the available corpus

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0060090 molecular adaptor activity 2 GO:0140096 catalytic activity, acting on a protein 2
Localization
GO:0005829 cytosol 2
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1640170 Cell Cycle 1
Complex memberships
KPC ubiquitin ligase complex

Evidence

Reading pass · 7 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 KPC2 (UBAC1) interacts with KPC1 through its UBL domain, with the 26S proteasome through its UBL and N-terminal UBA domains, and with polyubiquitylated proteins through its UBA domains, as shown by co-immunoprecipitation and domain-deletion experiments. Co-immunoprecipitation, domain deletion mutants, in vitro polyubiquitylation assay Molecular and cellular biology High 16227581
2005 KPC2 (UBAC1) association with KPC1 stabilizes KPC1 in a manner dependent on the STI1 domain of KPC2, as demonstrated by expression of STI1-deletion mutants in cells. Domain deletion mutagenesis, protein stability assay (cycloheximide chase implied), co-expression Molecular and cellular biology Medium 16227581
2005 KPC2 (UBAC1) mutants lacking either the N-terminal or C-terminal UBA domain could still support polyubiquitylation of p27 in vitro, but a KPC2 derivative lacking the STI1 domain was greatly impaired in p27 polyubiquitylation. In vitro ubiquitylation assay with domain-deletion mutants Molecular and cellular biology High 16227581
2005 Depletion of KPC2 (UBAC1) by RNAi inhibited p27 degradation at G1 phase; rescue experiments with domain mutants revealed that the N-terminal UBA domain of KPC2 is essential for p27 degradation in cells. RNA interference (RNAi) knockdown, rescue with domain mutants, cell cycle analysis Molecular and cellular biology High 16227581
2021 KPC2 (UBAC1) was identified as a novel interaction partner of CD95 (Fas) by unbiased proteomics; CD95/KPC2 interaction contributes to partial degradation of p105 (NF-κB1) and generation of p50 homodimers, which transcriptionally represses NF-κB-driven gene expression independently of CD95L. Unbiased proteomics (pull-down/MS), co-immunoprecipitation, NF-κB reporter assay, p105/p50 immunoblot iScience Medium 34917906
2021 KPC2 (UBAC1) interacts with the C-terminal region of CD95 and acts as an adaptor to recruit RelA (p65) and KPC1 (the E3 ubiquitin ligase), which promotes degradation of p105 into p50. Co-immunoprecipitation with deletion constructs, proximity ligation or co-IP of KPC1/RelA complex iScience Medium 34917906
2021 Loss of CD95 in triple-negative breast cancer (TNBC) cells releases KPC2 (UBAC1), limiting formation of the NF-κB inhibitory p50/p50 homodimer complex and promoting NF-κB activation and pro-inflammatory cytokine production. CD95 knockdown/knockout in TNBC cells, NF-κB activity measurement, cytokine ELISA iScience Medium 34917906

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrobial agents and chemotherapy 205 17562800
2003 Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. The Journal of antimicrobial chemotherapy 190 12615876
2006 Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrobial agents and chemotherapy 183 17145797
2009 Novel genetic environment of the carbapenem-hydrolyzing beta-lactamase KPC-2 among Enterobacteriaceae in China. Antimicrobial agents and chemotherapy 163 19620332
2008 Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrobial agents and chemotherapy 162 18332176
2003 Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrobial agents and chemotherapy 160 14638498
2009 Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrobial agents and chemotherapy 158 20008772
2020 The transferability and evolution of NDM-1 and KPC-2 co-producing Klebsiella pneumoniae from clinical settings. EBioMedicine 147 31911273
2008 Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrobial agents and chemotherapy 147 18227191
2006 Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrobial agents and chemotherapy 136 16940107
2009 Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. The Journal of antimicrobial chemotherapy 118 19525514
2017 Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering. mBio 115 29089425
2013 National surveillance study on carbapenem non-susceptible Klebsiella pneumoniae in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. PloS one 106 23894478
2015 Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrobial agents and chemotherapy 93 25666153
2012 Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. The Journal of biological chemistry 93 22843686
2015 Natural Variants of the KPC-2 Carbapenemase have Evolved Increased Catalytic Efficiency for Ceftazidime Hydrolysis at the Cost of Enzyme Stability. PLoS pathogens 92 26030609
2019 Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. The Journal of antimicrobial chemotherapy 91 30753572
2008 Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrobial agents and chemotherapy 91 18625772
2018 Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrobial agents and chemotherapy 89 29610205
2004 Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrobial agents and chemotherapy 83 15504876
2019 Whole genome assembly and functional portrait of hypervirulent extensively drug-resistant NDM-1 and KPC-2 co-producing Klebsiella pneumoniae of capsular serotype K2 and ST86. The Journal of antimicrobial chemotherapy 75 30843067
2008 Carbapenem-hydrolysing beta-lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, Brazil. The Journal of antimicrobial chemotherapy 70 19028717
2010 Detection of the new metallo-beta-lactamase VIM-19 along with KPC-2, CMY-2 and CTX-M-15 in Klebsiella pneumoniae. The Journal of antimicrobial chemotherapy 64 20522444
2005 Role of the UBL-UBA protein KPC2 in degradation of p27 at G1 phase of the cell cycle. Molecular and cellular biology 64 16227581
2019 Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. The Journal of antimicrobial chemotherapy 62 31127297
2013 Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China. Antimicrobial agents and chemotherapy 60 24323475
2008 High-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expression. Journal of medical microbiology 60 18287296
2020 Acquisition of Plasmid with Carbapenem-Resistance Gene blaKPC2 in Hypervirulent Klebsiella pneumoniae, Singapore. Emerging infectious diseases 59 32091354
2015 Molecular epidemiology of carbapenem resistant Enterobacteriaceae in Valle d'Aosta region, Italy, shows the emergence of KPC-2 producing Klebsiella pneumoniae clonal complex 101 (ST101 and ST1789). BMC microbiology 58 26552763
2021 Emergence and Expansion of a Carbapenem-Resistant Pseudomonas aeruginosa Clone Are Associated with Plasmid-Borne bla KPC-2 and Virulence-Related Genes. mSystems 57 34006625
2011 Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 57 21871227
2022 Structural Characterization of the D179N and D179Y Variants of KPC-2 β-Lactamase: Ω-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Antimicrobial agents and chemotherapy 55 35341315
2016 The IncP-6 Plasmid p10265-KPC from Pseudomonas aeruginosa Carries a Novel ΔISEc33-Associated bla KPC-2 Gene Cluster. Frontiers in microbiology 54 27014233
2015 Emergence of Raoultella ornithinolytica coproducing IMP-4 and KPC-2 carbapenemases in China. Antimicrobial agents and chemotherapy 50 26282422
2014 Coproduction of NDM-1 and KPC-2 in Enterobacter hormaechei from Brazil. Microbial drug resistance (Larchmont, N.Y.) 49 25473727
2012 Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276. Antimicrobial agents and chemotherapy 49 22687511
2016 Clonal dissemination of KPC-2 producing Klebsiella pneumoniae ST11 clone with high prevalence of oqxAB and rmtB in a tertiary hospital in China: results from a 3-year period. Annals of clinical microbiology and antimicrobials 47 26786830
2016 Nosocomial outbreak of KPC-2- and NDM-1-producing Klebsiella pneumoniae in a neonatal ward: a retrospective study. BMC infectious diseases 47 27733128
2010 Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Antimicrobial agents and chemotherapy 47 20421396
2019 Potential KPC-2 carbapenemase reservoir of environmental Aeromonas hydrophila and Aeromonas caviae isolates from the effluent of an urban wastewater treatment plant in Japan. Environmental microbiology reports 44 31106978
2013 Molecular Characterization of an Atypical IncX3 Plasmid pKPC-NY79 Carrying bla KPC-2 in a Klebsiella pneumoniae. Current microbiology 43 23728748
2012 Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrobial agents and chemotherapy 43 22330909
2017 Dissemination of Carbapenem-resistant Klebsiella pneumoniae clinical isolates with various combinations of Carbapenemases (KPC-2, NDM-1, NDM-4, and OXA-48) and 16S rRNA Methylases (RmtB and RmtC) in Vietnam. BMC infectious diseases 42 28676118
2018 Defining the architecture of KPC-2 Carbapenemase: identifying allosteric networks to fight antibiotics resistance. Scientific reports 41 30150677
2018 Hospital outbreak due to a Klebsiella pneumoniae ST147 clonal strain co-producing KPC-2 and VIM-1 carbapenemases in a tertiary teaching hospital in Northern Greece. International journal of antimicrobial agents 40 29654892
2020 Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam. Antimicrobial agents and chemotherapy 39 32015028
2019 MALDI-TOF MS based procedure to detect KPC-2 directly from positive blood culture bottles and colonies. Journal of microbiological methods 39 30849422
2013 Updated molecular epidemiology of carbapenem-non-susceptible Escherichia coli in Taiwan: first identification of KPC-2 or NDM-1-producing E. coli in Taiwan. BMC infectious diseases 39 24354657
2017 Discharge of KPC-2 genes from the WWTPs contributed to their enriched abundance in the receiving river. The Science of the total environment 37 28065546
2018 Comparative Genomic Analysis of a Clinical Isolate of Klebsiella quasipneumoniae subsp. similipneumoniae, a KPC-2 and OKP-B-6 Beta-Lactamases Producer Harboring Two Drug-Resistance Plasmids from Southeast Brazil. Frontiers in microbiology 36 29503635
2015 Coproduction of KPC-2 and IMP-10 in Carbapenem-Resistant Serratia marcescens Isolates from an Outbreak in a Brazilian Teaching Hospital. Journal of clinical microbiology 35 25878341
2016 Crystal Structures of KPC-2 and SHV-1 β-Lactamases in Complex with the Boronic Acid Transition State Analog S02030. Antimicrobial agents and chemotherapy 34 26729491
2016 Emergence of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close call. The Journal of antimicrobial chemotherapy 34 26817488
2011 First report of Klebsiella oxytoca strain coproducing KPC-2 and IMP-8 carbapenemases. Antimicrobial agents and chemotherapy 34 21422214
2020 Epidemiology of carbapenemase-producing Klebsiella pneumoniae in northern Portugal: Predominance of KPC-2 and OXA-48. Journal of global antimicrobial resistance 33 32348902
2025 Global emergence of Carbapenem-resistant Hypervirulent Klebsiella pneumoniae driven by an IncFIIK34 KPC-2 plasmid. EBioMedicine 31 40024096
2020 KPC-2 β-lactamase enables carbapenem antibiotic resistance through fast deacylation of the covalent intermediate. The Journal of biological chemistry 31 33273017
2009 Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 and ArmA 16S rRNA methylase conferring high-level aminoglycoside resistance in carbapenem-resistant Enterobacter cloacae in China. Diagnostic microbiology and infectious disease 31 19903584
2014 Mix and match of KPC-2 encoding plasmids in Enterobacteriaceae-comparative genomics. Diagnostic microbiology and infectious disease 30 24743043
2009 Structural and biochemical characterization of the interaction between KPC-2 beta-lactamase and beta-lactamase inhibitor protein. Biochemistry 30 19731932
2022 Detection of carbapenem-resistant hypervirulent Klebsiella pneumoniae ST11-K64 co-producing NDM-1 and KPC-2 in a tertiary hospital in Wuhan. The Journal of hospital infection 29 36183928
2020 Cyclic boronates as versatile scaffolds for KPC-2 β-lactamase inhibition. RSC medicinal chemistry 29 33479650
2018 KPC-2 carbapenemase-producing Pseudomonas aeruginosa reaching Germany. The Journal of antimicrobial chemotherapy 29 29590370
2015 Emergence of Carbapenemase Producing Klebsiella Pneumonia and Spread of KPC-2 and KPC-17 in Taiwan: A Nationwide Study from 2011 to 2013. PloS one 29 26384242
2019 Virulence factors and clinical patterns of multiple-clone hypermucoviscous KPC-2 producing K. pneumoniae. Heliyon 28 31286076
2013 Virulence of Klebsiella pneumoniae isolates harboring bla KPC-2 carbapenemase gene in a Caenorhabditis elegans model. PloS one 28 23844109
2013 Hospital clonal dissemination of Enterobacter aerogenes producing carbapenemase KPC-2 in a Chinese teaching hospital. Journal of medical microbiology 28 24273320
2012 Characterization of a novel Klebsiella pneumoniae sequence type 476 carrying both bla KPC-2 and bla IMP-4. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 28 22271301
2020 Outbreak of KPC-2 Carbapenem-resistant Klebsiella pneumoniae ST76 and Carbapenem-resistant K2 Hypervirulent Klebsiella pneumoniae ST375 strains in Northeast China: molecular and virulent characteristics. BMC infectious diseases 26 32616018
2021 Molecular Epidemiology of mcr-1, bla KPC-2, and bla NDM-1 Harboring Clinically Isolated Escherichia coli from Pakistan. Infection and drug resistance 25 33888998
2020 Clinical and Molecular Description of a High-Copy IncQ1 KPC-2 Plasmid Harbored by the International ST15 Klebsiella pneumoniae Clone. mSphere 25 33028683
2019 A Phage-Like Plasmid Carrying bla KPC-2 Gene in Carbapenem-Resistant Pseudomonas aeruginosa. Frontiers in microbiology 25 30949157
2018 Phenylboronic Acid Derivatives as Validated Leads Active in Clinical Strains Overexpressing KPC-2: A Step against Bacterial Resistance. ChemMedChem 25 29356380
2018 A Fatal Bacteremia Caused by Hypermucousviscous KPC-2 Producing Extensively Drug-Resistant K64-ST11 Klebsiella pneumoniae in Brazil. Frontiers in medicine 25 30298131
2018 Conformational Intermediate That Controls KPC-2 Catalysis and Beta-Lactam Drug Resistance. ACS catalysis 25 30637173
2021 Bloodstream Infections caused by Klebsiella pneumoniae and Serratia marcescens isolates co-harboring NDM-1 and KPC-2. Annals of clinical microbiology and antimicrobials 24 34461917
2019 Emergence and Characterization of a Novel IncP-6 Plasmid Harboring bla KPC-2 and qnrS2 Genes in Aeromonas taiwanensis Isolates. Frontiers in microbiology 24 31572337
2023 Tautomer-Specific Deacylation and Ω-Loop Flexibility Explain the Carbapenem-Hydrolyzing Broad-Spectrum Activity of the KPC-2 β-Lactamase. Journal of the American Chemical Society 23 36972204
2021 Genetic Diversity of Multidrug-Resistant Pseudomonas aeruginosa Isolates Carrying bla VIM-2 and bla KPC-2 Genes That Spread on Different Genetic Environment in Colombia. Frontiers in microbiology 22 34512563
2021 CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. iScience 22 34917906
2020 Nanopore MinION Sequencing Reveals Possible Transfer of bla KPC-2 Plasmid Across Bacterial Species in Two Healthcare Facilities. Frontiers in microbiology 22 32973725
2014 First report of KPC-2 Carbapenemase-producing Klebsiella pneumoniae in Japan. Antimicrobial agents and chemotherapy 22 24566171
2022 Diversity of Ceftazidime-Avibactam Resistance Mechanism in KPC2-Producing Klebsiella pneumoniae Under Antibiotic Selection Pressure. Infection and drug resistance 21 36003991
2021 Characterization of Carbapenem-Resistant Klebsiella pneumoniae ST15 Clone Coproducing KPC-2, CTX-M-15 and SHV-28 Spread in an Intensive Care Unit of a Tertiary Hospital. Infection and drug resistance 21 33688212
2017 Characterization of mobile genetic elements carrying VIM-1 and KPC-2 carbapenemases in Citrobacter freundii isolates in Madrid. International journal of medical microbiology : IJMM 21 28711315
2016 A cluster of KPC-2 and VIM-2-producing Klebsiella pneumoniae ST833 isolates from the pediatric service of a Venezuelan Hospital. BMC infectious diseases 21 27770796
2013 Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria. Journal of biomolecular structure & dynamics 21 23600675
2021 Local interactions with the Glu166 base and the conformation of an active site loop play key roles in carbapenem hydrolysis by the KPC-2 β-lactamase. The Journal of biological chemistry 20 34022225
2021 Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Sequence Type 11 Due to a Mutation in Plasmid-Borne bla kpc-2 to bla kpc-33, in Henan, China. Infection and drug resistance 19 34007191
2021 Emergence of ST39 carbapenem-resistant Klebsiella pneumoniae producing VIM-1 and KPC-2. Microbial pathogenesis 18 34954336
2019 A novel plasmid carrying carbapenem-resistant gene bla KPC-2 in Pseudomonas aeruginosa. Infection and drug resistance 18 31190916
2018 Boronic acid inhibitors of the class A β-lactamase KPC-2. Bioorganic & medicinal chemistry 18 29784271
2014 Phenotypic and enzymatic comparative analysis of the KPC variants, KPC-2 and its recently discovered variant KPC-15. PloS one 18 25360633
2013 Dissemination of the KPC-2 carbapenemase in non-Klebsiella pneumoniae enterobacterial isolates from Colombia. International journal of antimicrobial agents 18 23664581
2021 Distribution of β-Lactamase Genes and Genetic Context of bla KPC-2 in Clinical Carbapenemase-Producing Klebsiella pneumoniae Isolates. Infection and drug resistance 16 33536766
2021 Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseri. Antimicrobial agents and chemotherapy 16 33972237
2021 Deciphering the Epidemiological Characteristics and Molecular Features of bla KPC-2- or bla NDM-1-Positive Klebsiella pneumoniae Isolates in a Newly Established Hospital. Frontiers in microbiology 16 34858362
2018 Endemicity of the High-Risk Clone Klebsiella pneumoniae ST340 Coproducing QnrB, CTX-M-15, and KPC-2 in a Brazilian Hospital. Microbial drug resistance (Larchmont, N.Y.) 16 30543470
2014 Evaluation of inhibitory action of novel non β-lactam inhibitor against Klebsiella pneumoniae carbapenemase (KPC-2). PloS one 16 25265157
2011 Identification of bla KPC-2 on different plasmids of three Morganella morganii isolates. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 15 21874606

Missed literature

Know a paper Affinage missed for UBAC1? Flag it for the maintainers and the community.

No submissions yet.